Funder: Fanconi Cancer Foundation
Due Dates (Anticipated): March 2027 (Letter of Intent)
Funding Amounts: $25,000–$250,000 per proposal; typically 1–2 years
Summary: Supports interdisciplinary and translational research to treat, control, or cure Fanconi anemia and address associated cancers.
Key Information: A Letter of Intent is mandatory; full proposals are accepted by invitation only.
Description
The Fanconi Cancer Foundation (FCF) supports interdisciplinary and translational research that can rapidly advance therapies or strategies to treat, control, or cure Fanconi anemia (FA). Its highest priority is defining how Fanconi-associated cancers arise and developing approaches to prevention, early detection, treatment, and cure. Awards support both preclinical and clinical studies, with an emphasis on high-impact projects that could shift understanding of FA and clinical care, including work that typically would not receive NIH or other federal funding.
Other priorities include gene therapy and gene editing, predictors and treatments of bone marrow failure and related malignancies, systemic and aging manifestations of FA, practical quality-of-life strategies, data analytics, and shared research resources. Researchers new to FA and those previously funded by FCF are encouraged to apply.
